Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q1 FY2025 Earnings Presentation
16 slides from Piramal Pharma's earnings presentation, July 2024
Slide 1: Piramal Pharma Limited Q1FY25 Results
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Piramal Pharma Limited Q1FY25 Results July 2024
Slide 2: Disclaimer
Piramal Pharma Limited – Q1FY25 Results Presentation Page 2 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommend
Slide 3: Key Performance Highlights of Q1FY25
Piramal Pharma Limited – Q1FY25 Results Presentation Page 3 Key Performance Highlights of Q1FY25 Key Highlights Revenue and EBITDA Performance Revenue EBITDA Margin (in ₹ Cr.) ❖ In Q1FY25, Revenue from Operations grew by 12% YoY and EBITDA grew 31% YoY 10% 11% Business Segment Revenues (in ₹ Cr.) Yo
Slide 4: Business-wise Performance
Piramal Pharma Limited – Q1FY25 Results Presentation Page 4 Business-wise Performance
Slide 5: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q1FY25 Results Presentation Page 5 Contract Development and Manufacturing Organization Business Performance Highlights Revenue Growth in Q1FY25 (in ₹ Cr.) ❖ Market Outlook – Early signs of improvement in biotech funding. Need to see few more consistent quarters to establish
Slide 6: Continue to Maintain Best-in-Class Quality Track Record
Piramal Pharma Limited – Q1FY25 Results Presentation Page 6 Continue to Maintain Best-in-Class Quality Track Record 8 36 172 Zero Successful USFDA Successful regulatory Successful customer inspections since inspections in FY24 audits in FY24 OAIs1,2 January 2023 ✓ PPDS Ahmedabad, India - Inspected i
Slide 7: Complex Hospital Generics Business
Piramal Pharma Limited – Q1FY25 Results Presentation Page 7 Complex Hospital Generics Business Performance Highlights Revenue Growth in Q1FY25 ❖ Inhalation Anesthesia (IA) (in ₹ Cr.) • Robust demand for Sevoflurane & Isoflurane – Steady volume growth offset by price erosion in the USA. Impact on mar
Slide 8: India Consumer Healthcare Business
Piramal Pharma Limited – Q1FY25 Results Presentation Page 8 India Consumer Healthcare Business Performance Highlights Revenue Growth in Q1FY25 ❖ New Product launches - 7 new products and 10 new SKUs launched in Q1FY25. We have (in ₹ Cr.) launched 150+ new products and SKUs in the last three years 26
Slide 9: Sustainability Initiatives
Piramal Pharma Limited – Q1FY25 Results Presentation Page 9 Sustainability Initiatives
Slide 10: Glimpses of our Sustainability Initiatives in Q1FY25
Piramal Pharma Limited – Q1FY25 Results Presentation Page 10 Glimpses of our Sustainability Initiatives in Q1FY25 Pride Month – Celebrating Diversity World Environment Day – Sapling Blood Donation Camp – Employee and Inclusion plantation drives across several sites contributing to community service
Slide 11: Our Key Sustainability Agenda for FY2025
Piramal Pharma Limited – Q1FY25 Results Presentation Page 11 Our Key Sustainability Agenda for FY2025 Climate Change ▪ Work towards YoY reduction in our Scope 1, 2 and 3 GHG (Greenhouse Gas) emissions Management ▪ Successful verification of GHG emission reduction targets by SBTi (Science Based Targe
Slide 12: Recognition for our Sustainability Initiatives
Piramal Pharma Limited – Q1FY25 Results Presentation Page 12 Recognition for our Sustainability Initiatives Piramal Pharma Limited was honoured as one of the top Sustainable Organizations at the 3rd edition of “Times Now Global Sustainability Alliance Sustainable Organizations 2024.” The summit was
Slide 13: Financials
Piramal Pharma Limited – Q1FY25 Results Presentation Page 13 Financials
Slide 14: Consolidated Financials Highlights
Piramal Pharma Limited – Q1FY25 Results Presentation Page 14 Consolidated Financials Highlights (in ₹ Cr. or as stated) Reported Financials Particulars Q1FY25 Q1FY24 YoY Change Revenue from Operations* 1,951 1,749 12% CDMO 1,057 898 18% CHG 631 617 2% ICH 264 239 10% EBITDA 224 171 31% EBITDA Margin
Slide 15: Dial-in details for Q1FY25 Earnings Conference Call
Piramal Pharma Limited – Q1FY25 Results Presentation Page 15 Dial-in details for Q1FY25 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 05:00 PM IST 1 800 120 1221 (Toll free number) USA – 07:30 AM Toll free number Conferen
Slide 16: For Investor Queries
Piramal Pharma Limited – Q1FY25 Results Presentation Page 16 For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com